Press Release Archives

Einstein Researchers Develop Novel Drug That Regenerates Erectile Nerves Damaged by Prostate Surgery

April 19, 2021

(BRONX, NY)— Researchers at Albert Einstein College of Medicine have developed a topical drug that regenerates and restores the function of erectile nerves damaged by radical prostatectomy, the most common treatment for localized prostate cancer. The drug was tested in rats, and the findings were published online today in JCI Insight. These images show neurons cultured in petri dishes and treated

Novel drug regenerates erectile nerves damaged by prostate surgery

April 19, 2021

Researchers have developed a topical drug that regenerates and restores the function of erectile nerves damaged by radical prostatectomy, the most common treatment for localized prostate cancer. The drug was tested in rats.

New treatment for ED after prostate surgery being developed, researchers say

April 19, 2021

Men undergoing surgery for prostate cancer may no longer have to live with erectile dysfunction afterward, thanks to an innovative new treatment, researchers said in a paper published Monday by JCI Insight. The treatment, developed at Albert Einstein College of Medicine in New York City, involves the surgical implantation of a topical drug that regenerates and restores the function of

Hope for prostate cancer patients as experimental drug ‘may allow thousands of men left impotent from drastic surgery to get erections again

April 19, 2021

An experimental nerve-growing drug could revolutionise the sex lives of prostate cancer sufferers, scientists say. Thousands of men diagnosed with the disease require drastic treatment to remove the organ, which sits in the pelvis and is about the size of a ping pong ball. But it can damage nerves that control blood supply to the penis, leaving patients completely unable

Biotech Companies Seek to Restore Functions to Spinal-Cord Injury Patients

March 11, 2021

Stem cells, gene therapy among treatments under study for paralyzing injuries Biotechnology companies and researchers are studying treatments that could help patients with spinal-cord injuries recover abilities to move and function that they have lost. Each year about 18,000 Americans suffer spinal-cord injuries, which are often caused by automobile accidents, falls, violence and sports injuries, according to the National Spinal

New Therapy for Corneal Burns

February 3, 2021

New York, NY: In a study published online on January 8 in Translational Vision, Science and Technology, Albert Einstein College of Medicine scientists showed that their novel wound-healing therapy speeds the healing of corneal alkaline burns and may improve on current therapies that have limited success against such burns. Researchers in the lab of co-senior author David Sharp, Ph.D., had previously

MicroCures Announces Issuance of New European Patent Providing Broad Protection for First-of-its-Kind Cell Movement Decelerator Technology

May 20, 2020

Latest Patent Further Strengthens Intellectual Property Portfolio Covering Novel Platform for Precisely Controlling Core Cell Migration Mechanisms Decelerator Technology Has Key Potential Applications in Treatment of Cancer and Fibrosis and Serves as Key Complement to Company’s Cell Motility Accelerator Platform for Enhanced Tissue Repair New York, NY – MicroCures, a biopharmaceutical company developing novel therapeutics that harness the body’s innate regenerative

MicroCures Announces Material Transfer Agreement with Henry M. Jackson Foundation for the Advancement of Military Medicine to Support Preclinical Study of siFi2 for Spinal Cord Regeneration Following Injury

February 19, 2020

U.S. Department of Defense Researchers to Study Ability of siFi2 to Drive Axon Regeneration and Functional Recovery following Spinal Cord Injury New York, NY – MicroCures, a biopharmaceutical company developing novel therapeutics that harness the body’s innate regenerative mechanisms to accelerate tissue repair, today announced that it has entered into a material transfer agreement (MTA) with the Henry M. Jackson Foundation

MicroCures Advances Burn Wound Healing Program Under Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR)

January 28, 2020

$1 Million in Funding from the USAISR Supporting Collaborative Research Project Pilot Animal Study Successfully Completed; Larger Preclinical Study Underway New York, NY – MicroCures, a biopharmaceutical company developing novel therapeutics that harness the body’s innate regenerative mechanisms to accelerate tissue repair, today announced the advancement of its ongoing collaborative research project with the United States Army Institute of Surgical Research

MicroCures Announces Issuance of New Patent Covering First-of-its-Kind Cell Movement Decelerator Technology with Potential Applications in Oncology and Fibrosis

January 14, 2020

New Japanese Patent Further Strengthens Intellectual Property Portfolio Covering Company’s Novel Platform for Precisely Controlling Core Cell Migration Mechanisms Decelerator Technology Serves as Key Complement to Company’s Cell Motility Accelerator Platform for Enhanced Tissue Repair New York, NY – MicroCures, a biopharmaceutical company developing novel therapeutics that harness the body’s innate regenerative mechanisms to accelerate tissue repair, today announced the issuance

Category: Press Release